In summary, we have identified Bcl-XL as an important regulator of CLL drug resistance, we have shown that Bcl-XL is predominantly regulated via non-canonical NF-κB signaling and that interfering with this signaling pathway can tip the balance of resistant CLL cells towards apoptosis sensitivity. The gene discussed is NFKB1; the disease is B-cell chronic lymphocytic leukemia.